[Form 4] Atara Biotherapeutics, Inc Insider Trading Activity
Yanina Grant-Huerta, Chief Accounting Officer and Director of Atara Biotherapeutics (ATRA), reported automatic share sales on August 18, 2025 to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units. The filing lists three automatic dispositions executed via broker at weighted-average prices of approximately $11.61 per share, resulting in reported beneficial ownership of 35,258 shares after the transactions. The sales were executed pursuant to a sale-to-cover provision in the award agreement and the report was signed by an attorney-in-fact on August 20, 2025.
Yanina Grant-Huerta, Chief Accounting Officer e membro del consiglio di Atara Biotherapeutics (ATRA), ha comunicato vendite automatiche di azioni il 18 agosto 2025 per far fronte agli obblighi fiscali derivanti dalla maturazione di restricted stock unit precedentemente concesse. La dichiarazione riporta tre cessioni automatiche eseguite tramite broker a prezzi medi ponderati di circa 11,61$ per azione, determinando una propriet脿 effettiva di 35.258 azioni dopo le transazioni. Le vendite sono state effettuate in conformit脿 a una clausola di sale-to-cover prevista nell'accordo di assegnazione e il rapporto 猫 stato firmato da un procuratore il 20 agosto 2025.
Yanina Grant-Huerta, Chief Accounting Officer y directora de Atara Biotherapeutics (ATRA), inform贸 ventas autom谩ticas de acciones el 18 de agosto de 2025 para cubrir obligaciones fiscales vinculadas a la consolidaci贸n de restricted stock units previamente otorgadas. El informe detalla tres disposiciones autom谩ticas ejecutadas a trav茅s de un br贸ker a precios promedio ponderados de aproximadamente 11,61 $ por acci贸n, resultando en una propiedad beneficiaria de 35.258 acciones despu茅s de las operaciones. Las ventas se realizaron conforme a una cl谩usula de venta para cubrir (sale-to-cover) incluida en el acuerdo de la concesi贸n y el informe fue firmado por un apoderado el 20 de agosto de 2025.
鞎茧媹雮� 攴鸽灅nt-頊挫棎毳错儉(Yanina Grant-Huerta) 鞎勴儉霛� 氚旍澊鞓ろ厡霛柬摠韹膘姢(ATRA) 斓滉碃須岅硠毂呾瀯鞛� 瓴� 鞚挫偓電� 2025雲� 8鞗� 18鞚�, 鞚挫爠鞐� 攵�鞐悳 鞝滍暅欤检嫕靾橃棳(RSU)鞚� 旆摑鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 鞛愲彊 欤检嫕 毵り皝鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 欷戧皽鞚胳潉 韱淀暣 鞎� 欤茧嫻 11.61雼煬鞚� 臧�欷戫弶攴犼皜瓴╈溂搿� 鞁ろ枆霅� 靹� 瓯挫潣 鞛愲彊 觳橂秳鞚� 旮办灛霅橃柎 鞛堨溂氅�, 瓯半灅 頉� 氤搓碃霅� 鞁れ唽鞙� 欤检嫕靾橂姅 35,258欤�鞛呺媹雼�. 頃措嫻 毵り皝鞚� 靾橃棳瓿勳暯鞚� sale-to-cover 臁绊暛鞐� 霐半澕 鞚措（鞏挫瓿�, 氤搓碃靹滊姅 2025雲� 8鞗� 20鞚� 雽�毽澑鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.
Yanina Grant-Huerta, Chief Accounting Officer et administratrice d'Atara Biotherapeutics (ATRA), a d茅clar茅 des ventes automatiques d'actions le 18 ao没t 2025 afin de satisfaire les obligations fiscales li茅es 脿 la consolidation de restricted stock units ant茅rieurement accord茅es. Le dossier indique trois cessions automatiques ex茅cut茅es via un courtier 脿 des prix moyens pond茅r茅s d'environ 11,61 $ par action, entra卯nant une participation b茅n茅ficiaire d茅clar茅e de 35 258 actions apr猫s les op茅rations. Les ventes ont 茅t茅 r茅alis茅es conform茅ment 脿 une clause de vente pour couvrir (sale-to-cover) pr茅vue dans l'accord d'attribution et le rapport a 茅t茅 sign茅 par un mandataire le 20 ao没t 2025.
Yanina Grant-Huerta, Chief Accounting Officer und Direktorin von Atara Biotherapeutics (ATRA), meldete am 18. August 2025 automatische Aktienverk盲ufe zur Erf眉llung steuerlicher Abzugsverpflichtungen im Zusammenhang mit der Vesting von zuvor gew盲hrten Restricted Stock Units. Die Meldung enth盲lt drei automatische Ver盲u脽erungen, die 眉ber einen Broker zu einem gewichteten Durchschnittspreis von etwa 11,61 $ pro Aktie ausgef眉hrt wurden, wodurch nach den Transaktionen ein meldepflichtiges Eigentum von 35.258 Aktien verbleibt. Die Verk盲ufe erfolgten gem盲脽 einer Sale-to-Cover-Klausel im Zuteilungsdokument, und der Bericht wurde am 20. August 2025 von einem Bevollm盲chtigten unterzeichnet.
- Disclosure compliance: Form 4 was filed and signed, showing adherence to Section 16 reporting requirements
- Routine equity plan action: Sales were sale-to-cover transactions tied to RSU vesting, a common administrative practice
- Reduction in beneficial ownership: Reported beneficial ownership after transactions is 35,258 shares, reflecting a decrease due to sales
- Insider sales executed: Automatic dispositions occurred on 08/18/2025 at an average price of approximately $11.61 per share
Insights
TL;DR: Routine sale-to-cover for RSU tax withholding; no new compensation grants or unusual trading patterns disclosed.
The Form 4 shows automatic dispositions on August 18, 2025 tied to RSU vesting, not open-market discretionary sales. The reported weighted-average price (~$11.61) reflects broker execution on behalf of multiple employees, and the post-transaction beneficial ownership is 35,258 shares. For investors, this is a routine administrative event that reduces the officer's share count but does not, by itself, indicate a change in company outlook or material insider reallocation.
TL;DR: Disclosure meets Section 16 reporting requirements; sale-to-cover practice is standard and indicates compliance.
The disclosure explicitly states the sales were automatic to satisfy tax withholding on vested RSUs and were handled via broker sale-to-cover. The filing is properly executed by an attorney-in-fact and includes an explanation of the sale price calculation. This demonstrates adherence to reporting protocols and internal equity compensation procedures, with no indications of undisclosed agreements or exceptions.
Yanina Grant-Huerta, Chief Accounting Officer e membro del consiglio di Atara Biotherapeutics (ATRA), ha comunicato vendite automatiche di azioni il 18 agosto 2025 per far fronte agli obblighi fiscali derivanti dalla maturazione di restricted stock unit precedentemente concesse. La dichiarazione riporta tre cessioni automatiche eseguite tramite broker a prezzi medi ponderati di circa 11,61$ per azione, determinando una propriet脿 effettiva di 35.258 azioni dopo le transazioni. Le vendite sono state effettuate in conformit脿 a una clausola di sale-to-cover prevista nell'accordo di assegnazione e il rapporto 猫 stato firmato da un procuratore il 20 agosto 2025.
Yanina Grant-Huerta, Chief Accounting Officer y directora de Atara Biotherapeutics (ATRA), inform贸 ventas autom谩ticas de acciones el 18 de agosto de 2025 para cubrir obligaciones fiscales vinculadas a la consolidaci贸n de restricted stock units previamente otorgadas. El informe detalla tres disposiciones autom谩ticas ejecutadas a trav茅s de un br贸ker a precios promedio ponderados de aproximadamente 11,61 $ por acci贸n, resultando en una propiedad beneficiaria de 35.258 acciones despu茅s de las operaciones. Las ventas se realizaron conforme a una cl谩usula de venta para cubrir (sale-to-cover) incluida en el acuerdo de la concesi贸n y el informe fue firmado por un apoderado el 20 de agosto de 2025.
鞎茧媹雮� 攴鸽灅nt-頊挫棎毳错儉(Yanina Grant-Huerta) 鞎勴儉霛� 氚旍澊鞓ろ厡霛柬摠韹膘姢(ATRA) 斓滉碃須岅硠毂呾瀯鞛� 瓴� 鞚挫偓電� 2025雲� 8鞗� 18鞚�, 鞚挫爠鞐� 攵�鞐悳 鞝滍暅欤检嫕靾橃棳(RSU)鞚� 旆摑鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 鞛愲彊 欤检嫕 毵り皝鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 欷戧皽鞚胳潉 韱淀暣 鞎� 欤茧嫻 11.61雼煬鞚� 臧�欷戫弶攴犼皜瓴╈溂搿� 鞁ろ枆霅� 靹� 瓯挫潣 鞛愲彊 觳橂秳鞚� 旮办灛霅橃柎 鞛堨溂氅�, 瓯半灅 頉� 氤搓碃霅� 鞁れ唽鞙� 欤检嫕靾橂姅 35,258欤�鞛呺媹雼�. 頃措嫻 毵り皝鞚� 靾橃棳瓿勳暯鞚� sale-to-cover 臁绊暛鞐� 霐半澕 鞚措（鞏挫瓿�, 氤搓碃靹滊姅 2025雲� 8鞗� 20鞚� 雽�毽澑鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.
Yanina Grant-Huerta, Chief Accounting Officer et administratrice d'Atara Biotherapeutics (ATRA), a d茅clar茅 des ventes automatiques d'actions le 18 ao没t 2025 afin de satisfaire les obligations fiscales li茅es 脿 la consolidation de restricted stock units ant茅rieurement accord茅es. Le dossier indique trois cessions automatiques ex茅cut茅es via un courtier 脿 des prix moyens pond茅r茅s d'environ 11,61 $ par action, entra卯nant une participation b茅n茅ficiaire d茅clar茅e de 35 258 actions apr猫s les op茅rations. Les ventes ont 茅t茅 r茅alis茅es conform茅ment 脿 une clause de vente pour couvrir (sale-to-cover) pr茅vue dans l'accord d'attribution et le rapport a 茅t茅 sign茅 par un mandataire le 20 ao没t 2025.
Yanina Grant-Huerta, Chief Accounting Officer und Direktorin von Atara Biotherapeutics (ATRA), meldete am 18. August 2025 automatische Aktienverk盲ufe zur Erf眉llung steuerlicher Abzugsverpflichtungen im Zusammenhang mit der Vesting von zuvor gew盲hrten Restricted Stock Units. Die Meldung enth盲lt drei automatische Ver盲u脽erungen, die 眉ber einen Broker zu einem gewichteten Durchschnittspreis von etwa 11,61 $ pro Aktie ausgef眉hrt wurden, wodurch nach den Transaktionen ein meldepflichtiges Eigentum von 35.258 Aktien verbleibt. Die Verk盲ufe erfolgten gem盲脽 einer Sale-to-Cover-Klausel im Zuteilungsdokument, und der Bericht wurde am 20. August 2025 von einem Bevollm盲chtigten unterzeichnet.
FAQ
What did Yanina Grant-Huerta report on Form 4 for ATRA?
Why were shares sold according to the Form 4 for ATRA?
How many shares were sold and at what price in the ATRA Form 4?
Who signed the Form 4 for Yanina Grant-Huerta?
Does the Form 4 indicate any discretionary open-market insider selling?
